The European Commission has issued clearance to market Novo Nordisk's diabetes therapies, Tresiba and Ryzodeg, across 27 European Union (EU) states.
Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and Denmark during the first six months of 2013 and in other states all through 2013 and 2014.
The company will offer Tresiba in two concentrations with 80 and 160 units per injection doses.
Another insulin Ryzodeg, the brand name for insulin degludec/insulin aspart, will be introduced a year after Tresiba launch.
Both the products will be made available in FlexTouch prefilled insulin pen.
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said the marketing authorizations are the important mile stones for the company and diabetes treatment.
"We look forward to making Tresiba and Ryzodeg available to many people with diabetes in Europe," Krogsgaard Thomsen added.
Tresiba is considered as the first basal insulin analogue offering flexibility of adjusting the time of injection depending on the requirement in addition to acting for longer duration.
Ryzodeg constitutes basal insulin degludec in a soluble formulation along with insulin aspart.
